Genetic Technologies gets tough

By Kate McDonald
Monday, 14 July, 2008


Genetic Technologies (ASX: GTG) will enforce its exclusive rights to perform diagnostic testing of the BRCA1 and BRCA2 breast cancer genes in Australia and New Zealand.

The company has been paying ongoing licence fees to Myriad Genetics for exclusive rights to perform diagnostic testing but has been allowing other service providers to perform BRCA testing for the last five years.

Genetic Technologies said in a statement it was now enforcing those exclusive rights, preventing several laboratories throughout the country from performing the test.

It said it had invested several million dollars in a high-throughput molecular diagnostic laboratory and had reduced turnaround time to four weeks.

Related Articles

Breakthrough drug prevents long COVID symptoms in mice

Mice treated with the antiviral compound were protected from long-term brain and lung dysfunction...

Antibiotics hinder vaccine response in infants

Infants who received antibiotics in the first few weeks of life had significantly lower levels of...

Colossal announces 'de-extinction' of the dire wolf

Colossal Biosciences has announced what it describes as the rebirth of the dire wolf, which would...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd